Loading asset research
Greenwich LifeSciences Inc. Common Stock
GLSINasdaq · USD · StocksQuote as of · Exchange session not verified$15.40
+2.26%
Today
GLSI
Loading 1D prices…
Market cap
$226.8M
Volume
74.8K
52w high
$34.1052w low
$7.78Company profile
Greenwich LifeSciences Inc. Common Stock
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Stafford, TX, United States
Fiscal year end
1231
CIK
1799788
Session & valuation
Open$15.33
Previous close$15.06
Day high$15.60
Day low$15.09
30-day avg. volume118K
Outstanding shares14.7M
Diluted EPS-$1.43
Latest annual period
P/E (trailing)-10.77
P/E (forward)-18.84
Price / book72.88
Beta1.46
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ELDNEledon Pharmaceuticals Inc. Common Stock | $225.9M | $0.00 | — | -$0.52 | -0.36% | Buy |
| ADAGAdagene Inc. American Depositary Shares | $228.3M | $7.7M | -229.56% | -$0.30 | +2.72% | Buy |
| VRXAVeraxa Biotech AG Ordinary Shares | $233.3M | — | — | -$0.1989 | +0.61% | Unrated |
| KROSKeros Therapeutics Inc. Common Stock | $219.7M | $244.1M | +35.65% | $2.30 | -0.81% | Buy |
| WHWKWhitehawk Therapeutics Inc. Common Stock | $234.3M | $7.1M | -288.26% | -$0.33 | +0.98% | Buy |